We previous showed that, compared with those with a “granulocytic-monocytic progenitor (GMP) pattern” of differentiation, MDS patients with an immunophenotypic “common myeloid progenitor (CMP) pattern” of differentiation who received venetoclax-based therapy had a shorter cumulative time to complete remission and a longer recurrence-free survival duration, primarily because venetoclax can efficiently target only “CMP pattern” HSCs, whose survival depends on BCL2. Here, BCL2 is linked to myelodysplastic syndrome.